Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > BioSante Pharmaceuticals Common Stock Begins Trading On NASDAQ Global Market Today

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that its common stock will commence trading on the NASDAQ Global Market effective with the opening of the market today under the new ticker symbol "BPAX". BioSante announced on October 23 its intention to transfer its common stock listing from the American Stock Exchange to the NASDAQ.

BioSante Pharmaceuticals Common Stock Begins Trading On NASDAQ Global Market Today

LINCOLNSHIRE, IL | Posted on November 5th, 2007

"Moving to NASDAQ is another example of the progress we've made at BioSante," said Stephen M. Simes, BioSante's president and chief executive officer. "We believe listing on NASDAQ will bring added visibility and exposure to BioSante as well as improve our stock's liquidity."

"NASDAQ is delighted to have BioSante Pharmaceuticals among our 3,100 listed companies," said NASDAQ's Senior Vice President of New Listings and Capital Markets, Bob McCooey. "The pharmaceutical industry is an important sector to NASDAQ and we look forward to a longstanding partnership with BioSante."


About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine. Additional information is available online at .


NASDAQ® is the largest U.S. electronic stock market. With approximately 3,100 companies, it lists more companies and, on average, its systems trade more shares per day than any other U.S. market. NASDAQ is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit the NASDAQ website at or the NASDAQ NewsroomSM at .

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include the effect of the NASDAQ listing on BioSante, its common stock and investors. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that could cause actual results to differ materially from those expressed in such forward-looking statements include the ability of BioSante to continue to satisfy listing requirements of The NASDAQ Global Market and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which discussions also are incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please click here

BioSante Pharmaceuticals, Inc.
Phillip Donenberg

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Nanometrics Announces Upcoming Investor Events November 18th, 2015

Harris & Harris Group Portfolio Company, D-Wave Systems, Announces Multi-Year Agreement With Lockheed Martin November 16th, 2015

Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA November 16th, 2015

Harris & Harris Group Portfolio Company, D-Wave Systems, Announces the Sale of Its Latest Quantum Computer to Los Alamos National Laboratory November 11th, 2015


Nanoparticles simplify DNA identification and quantification November 27th, 2015

Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015

Electric fields remove nanoparticles from blood with ease November 24th, 2015

Production of Nanocapsules Containing Omega-3 Powder in Iran November 24th, 2015


'Material universe' yields surprising new particle November 28th, 2015

Iranian Scientists Discover New Catalyst to Remove Pharmaceutical Compounds from Wastewater November 28th, 2015

RAMAN Spectrometry Makes Characterization of Various Nanostructures Possible November 28th, 2015

Nanoparticles Boost Impact Resistance of Special Type of Polymer November 28th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic